SEC filing · 8-K

Immunome Inc.: Material agreement

Immunome amended its license agreement with Bristol-Myers Squibb to acquire patent rights and eliminate all future milestone and royalty payments.

Filed October 5, 2026

Positive for the company

What happened

Immunome entered into Amendment No. 4 to its license agreement with Bristol-Myers Squibb Company.

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov All documents of this filing

Back to Immunome Inc.

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.